RenovoRx, Inc.

Contributing Author

Recent Articles by RenovoRx, Inc.

Jun-04	RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd RNXT +7.71% GlobeNewswire
May-28	RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer RNXT +6.20% GlobeNewswire
May-26	RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP Platform Presented at the 2026 ASCO Annual Meeting RNXT GlobeNewswire
May-19	RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th RNXT GlobeNewswire
May-14	RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter RNXT GlobeNewswire
Apr-29	RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET RNXT GlobeNewswire
Apr-23	RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting RNXT -5.09% GlobeNewswire
Apr-14	Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP Therapy Platform Presented at 2026 SIR Annual Scientific Meeting RNXT GlobeNewswire
Apr-08	RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath Device for Targeted, Local Drug-Delivery via the Vasa Vasorum RNXT GlobeNewswire
Apr-01	RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 RNXT GlobeNewswire
Mar-30	RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update RNXT -5.61% RNXT -5.31% GlobeNewswire
Mar-26	RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment RNXT +5.45% GlobeNewswire
Mar-23	RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement RNXT +11.00% GlobeNewswire
Mar-20	RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET RNXT GlobeNewswire
Mar-18	RenovoRx Announces $10 Million at Market Private Placement RNXT +6.59% GlobeNewswire
Feb-27	RenovoRx Advancing RenovoCath Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum RNXT GlobeNewswire
Feb-26	RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting RNXT GlobeNewswire
Feb-10	RenovoRx Establishes RenovoCath Medical Advisory Board RNXT GlobeNewswire
Feb-05	RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer RNXT GlobeNewswire
Feb-04	RenovoRx Announces Clinical Data Supporting the TAMP Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting RNXT GlobeNewswire
Jan-28	RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting RNXT GlobeNewswire
Jan-20	RenovoRx Expands RenovoCath Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center RNXT GlobeNewswire
Jan-14	RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026 RNXT GlobeNewswire
Jan-08	RenovoRx To Announce Promising New Clinical Data Using its TAMP Therapy Platform in an Abstract to be Presented at ASCO GI 2026 RNXT +13.86% GlobeNewswire
Dec-11	RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026 RNXT GlobeNewswire
Dec-01	RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th RNXT -6.59% GlobeNewswire
Nov-19	RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th RNXT -6.38% GlobeNewswire
Nov-13	RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update RNXT -23.03% RNXT GlobeNewswire
Nov-06	RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD RNXT -6.23% GlobeNewswire
Nov-04	RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th RNXT -6.42% GlobeNewswire
Oct-27	RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET RNXT GlobeNewswire
Oct-09	RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baere, MD, PhD RNXT -7.44% GlobeNewswire
Sep-25	RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites RNXT GlobeNewswire
Sep-11	RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th RNXT +5.98% GlobeNewswire
Aug-06	RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath Device with Growing Customer Demand and Key Leadership Hire RNXT GlobeNewswire

RenovoRx, Inc.

Recent Articles by RenovoRx, Inc.

Upgrade your Finviz experience